- Lenvima(R) (lenvatinib): new options for the systemic treatment of thyroid cancer2016 | Publication without faculty affiliation
- Lenvatinib v léčbě radiorefrakterního papilárního karcinomu štítné žlázy2017 | Publication without faculty affiliation
- Neutralization of lenvatinib charge hampers encapsulation into ferritin nanocages2019 | Faculty of Science, Faculty of Mathematics and Physics
- Recent advances in tartgeted therapy of renal cell carcinoma2016 | First Faculty of Medicine
- The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib2022 | Faculty of Science
- Dlouhodobá odpověď na lenvatinib u pacienta s hepatocelulárním karcinomem - kazuistika2021 | Third Faculty of Medicine
- Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial2023 | First Faculty of Medicine
- Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study2023 | First Faculty of Medicine
- Pacientka s hepatocelulárním karcinomem a metastázami do plic: "Kolik lenvatinibu stačí?"2022 | Third Faculty of Medicine
- New possibilities of systemic treatment of thyroid cancer2018 | Publication without faculty affiliation
- Treatment of renal cell carcinoma - update 20172017 | First Faculty of Medicine
- New possibilities of targeted therapy of thyroid cancer2017 | Publication without faculty affiliation
- Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro2018 | Faculty of Science
- Pokročilý endometriální adenokarcinom a imunoterapie2022 | Faculty of Medicine in Pilsen
- The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care2021 | Faculty of Medicine in Pilsen
- News in the systemic treatment of advanced kidney cancer2016 | Publication without faculty affiliation
- Systemic treatment of hepatocellular carcinoma2022 | Third Faculty of Medicine
- Does the etiology of hepatocellular carcinoma matter in the choice of systemic therapy?2023 | Third Faculty of Medicine
- News in the treatment of thyroid cancer - view of an endocrinologist2020 | Second Faculty of Medicine
- The Significance of BRAFV600E Mutation in Thyroid Cancer in Terms of Novel Targeted Therapies - Overview of Current Knowledge and Studies2018 | Faculty of Medicine in Hradec Králové
- Immunotherapy of Renal Cell Carcinoma2017 | First Faculty of Medicine
- Treatment of metastatic renal cell carcinoma in higher lines - patients after progression on TKI and immune checkpoint inhibitor2022 | First Faculty of Medicine
- Porovnání výsledků léčby HCC sorafenibem ve studii SHARP a v klinické praxi2019 | First Faculty of Medicine
- Komentář ke studii2022 | First Faculty of Medicine